钇90放射性微球在肝脏恶性肿瘤中的应用及进展  

Application and progress of Yttrium-90 therapy in liver malignant tumors

作　　者：牛惠敏 王志恒 高石鑫 曾骞 李颖慧 韩玥 Niu Huimin;Wang Zhiheng;Gao Shixin;Zeng Qian;Li Yinghui;Han Yue(Department of Intervention,Hainan Cancer Hospital,Haikou 570302,Hainan,China;Department of Intervention,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]海南省肿瘤医院介入科,海南海口570312 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院介入科,北京100021

出　　处：《肝癌电子杂志》2021年第4期36-40,共5页Electronic Journal of Liver Tumor

摘　　要：肝脏恶性肿瘤包括原发性肝癌及肝转移癌,具有恶性程度高、死亡率高的特点。目前对于中晚期肝脏恶性肿瘤等不可手术患者,局部治疗是控制疾病进展的重要治疗手段。钇90(Yttrium-90,^(90)Y)放射性微球是基于传统的经动脉化疗栓塞术(transarterial chemoembolization,TACE),结合肿瘤近程精准放射治疗技术衍生而来。相对于传统TACE治疗,^(90)Y具有肿瘤反应率高、不良反应低以及生活质量好等优点。本文对^(90)Y放射性微球在肝脏恶性肿瘤的应用及进展进行综述。Liver malignant tumor includes primary liver cancer and liver metastatic cancer.Liver malignant tumor has the characteristics of high malignancy and high mortality.At present,for patients with advanced liver malignant tumors,local treatment is an important treatment method to control the progression of the disease.Yttrium-90(^(90)Y)radiation microspheres are derived from the traditional transarterial chemoembolization(TACE)treatment technology and combined with the tumor short-range precision radiotherapy technology.Compared with traditional TACE treatment,^(90)Y has the characteristics of high tumor response rate,low adverse response and better quality of life.This article reviews the application progress of ^(90)Y therapy in liver malignant tumors.

关 键 词：钇90放射性微球 放射介入术 选择性内放射治疗 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]